-
Media Release
Novartis Pharmaceuticals Corporation restructuring US field force to align with changing product portfolio and strategic growth priorities
-
Media Release
New “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers
-
Media Release
New “Stand Together for AD” campaign provides strength, support and important resources for 11 million Alzheimer’s caregivers
-
Media Release
Analysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection
-
Media Release
Analysis shows Novartis drug TOBI® associated with reduced mortality in cystic fibrosis patients with common lung infection
-
Media Release
Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
-
Media Release
Novartis gains FDA approval for Gilenya™, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
-
Media Release
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
-
Media Release
Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure
-
Media Release
US Affiliate of Novartis Strongly Disputes Claims of Past Discrimination in the US
-
Media Release
US Affiliate of Novartis Strongly Disputes Claims of Past Discrimination in the US
-
Media Release
Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court